We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Innovation in Cancer, Infectious Disease Research

Innovation in Cancer, Infectious Disease Research  content piece image
Stephen Isaacs, CEO of Aduro Biotech, at the launch of the IVRI on March 23. (Peg Skorpinski photos)
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Doctors have had great success using vaccines to boost the immune system to fight infectious diseases like smallpox and measles, but only recently have immune system boosters been tried against cancer.

The growing success of such attempts — a booming field called immunotherapy that was pioneered at UC Berkeley — proves that studying the way the immune system deals with these two types of invaders, cancer cells and pathogens, could greatly improve therapies for both.

This is the goal of UC Berkeley’s Immunotherapeutics and Vaccine Research Institute, launched last year to explore the commonalities of cancer and infectious disease, and use discoveries in one area to improve treatment in the other.

Russell Vance and his colleagues Daniel Portnoy, Michael Eichberg and IVRI faculty director David Raulet argued for this approach in a perspective piece appearing in the current issue of the journal Science Immunology.

“The two fields are dramatically intertwined … and have much to learn from each other. More interactiveness is likely to fuel major strides in both fields,” Raulet told the website Healthline News last week. In addition to directing IVRI, Raulet is the Esther and Wendy Schekman Chair in basic cancer biology.

In the video above, Vance, an associate professor of molecular and cell biology and a Howard Hughes Medical Institute investigator, and IVRI researcher Sarah Stanley discuss how basic discoveries in one field trigger insights in the other. Stanley is an assistant professor of molecular and cell biology and a tuberculosis researcher.

This article has been republished from materials provided by UC Berkeley. Note: material may have been edited for length and content. For further information, please contact the cited source.